Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

European Paediatric Influenza Analysis (EPIA) Group Formed To Quantify The Burden Of Seasonal Influenza In Children In Europe
The Netherlands Institute for Health Services Research (NIVEL) and SDI, a U.S. private-sector healthcare information company, announced the formation of the European Paediatric Influenza Analysis (EPIA) group, created to generate data needed to inform the decision process about paediatric influenza vaccination policy in individual European countries. Researchers from Denmark, England, Finland, Italy, the Netherlands, Scotland, Spain and Wales are participating; it is hoped that other countries will also join. EPIA was formed to address knowledge gaps highlighted in a recent European Centre for Disease Prevention and Control (ECDC) report that concluded that a key barrier to decision-making about paediatric flu vaccines is the lack of high-quality, European-specific data on disease burden, especially for young children. It is estimated by ECDC that at least 40,000 people die each year from influenza in the European Union (EU). EPIA will present the initial results from their research project at the 27th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) in June.

Statins May Be Linked To Muscle Damage
A recent study published in the Canadian Medical Association Journal (CMAJ) reports that patients taking statins with associated muscle complaints may have structural muscle damage.
News of the day
NexMed Announces Decision For Anti-Fungal Product
NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, announced the mutual decision with Novartis to terminate the licensing agreement for NM100060, a topically-applied treatment for onychomycosis, commonly known as nail fungus. NexMed entered into the exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.
Endocrinology

Three New Studies Give Clear Guidance On How To Better Recruit Volunteers For Alzheimer's Clinical Studies

Partnering with local physicians, working with local clinics, conducting educational seminars and health fairs were found to be the most effective tools in recruiting people for clinical studies "Clinical trials are very important. Not only do they drive forward dementia research but people who participate in clinical trials often experience positive benefits. Despite this a very small number of people are given the opportunity to participate in a dementia research trial. We must invest in clinical trials and use the unique value of the NHS to improve patient access to clinical trials. This will allow new treatments to reach people with dementia as soon as possible. "Communication is also key. It is important to ensure that people are given practical information about available trials and realistic advice about selection." Professor Clive Ballard Director of Research Alzheimer"s Society Notes - International Conference of Alzheimer"s Disease runs from 11 - 16 July 2009 for further information please visit ICAD - One in three people over 65 will die with dementia - Alzheimer"s Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer"s disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051. - Alzheimer"s Society champions the rights of people living with dementia and the millions of people who care for them. - Alzheimer"s Society works in England, Wales and Northern Ireland - Alzheimer"s Society needs to raise money to help people live well with dementia today and for research to find a cure for tomorrow. You can donate now by calling 0845 306 0898 or visiting http://www.alzheimers.org.uk Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009